

*Serial No. 09/502,176*

*Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use*

*Sixth Amendment and Response to Office Action*

*Filed: February 10, 2000*

*Page 5*

## REMARKS

The above-identified patent application is directed to a composition comprising a deglycosylated kringle 1-3 region fragment of a plasminogen protein. In this Amendment and Response to Office Action, applicants amend Claims 1, 4, 29, 35, 37 and 38, add new Claims 39-43, and cancel Claims 10-12, 30-34, and 36. Applicants respectfully submit that the amendments to the claims and newly submitted claims do not introduce any new matter. Claims 1-4, 6-9, 15, 16, 27, 29, 35, and 37-43 are pending upon entry of the amendments. Reexamination and reconsideration of the application are requested in view of the amendments and the following remarks.

### *Claim Rejections under 35 U.S.C. §103(a)*

The Examiner rejects Claims 1-4, 6-12, 15, 16, 29-33 and 35-38 under 35 U.S.C. §103(a) as obvious over U.S. Patent No. 5,837,682 to Folkman *et al.*, which is commonly owned with the present patent application. Applicants respectfully submit that the amendments to the claims as discussed below overcome the rejection and render the claims allowable.

The Examiner states that Claim 27 is allowable and that Claims 7, 12, 27 and 34 are free of the prior art.

Applicants have amended Claim 1 to incorporate the limitations of previously presented Claim 12, which the Examiner found to be free of the prior art. Accordingly, applicants respectfully submit that amended Claim 1 and dependent Claims 2-16 are allowable.

Applicants have added new Claim 39, which is based on Claim 1 and incorporates the limitations of previously presented Claim 7 or Claim 34, which the Examiner found to be free of the prior art. Applicants have added new Claim 40, which is dependent on new Claim 39. Applicants have amended Claims 29, 35, 37 and 38 to make

*Serial No. 09/502,176*

*Title: Deglycosylated Kringle I-3 Region Fragments of Plasminogen and Methods of Use*

*Sixth Amendment and Response to Office Action*

*Filed: February 10, 2000*

*Page 6*

them directly or indirectly dependent on new Claim 39. Applicants respectfully submit that Claim 39 and dependent Claims 29, 35, 37, 38 and 40 allowable.

Applicants have added new Claims 41-43, which depend from allowable Claim 27 and are based on previously presented Claims 8, 15 and 16. Applicants respectfully submit that Claims 41-43 are allowable.

Applicants have canceled Claims 10-12, 30-34, and 36 as redundant. Applicants have amended Claim 4 to correct antecedent basis.

In view of the foregoing, applicants assert that the amendments render the claims allowable. Therefore, applicants request withdrawal of the rejection under 35 U.S.C. §103(a) and allowance of the amended claims.

Serial No. 09/502,176

Title: *Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use*

Sixth Amendment and Response to Office Action

Filed: February 10, 2000

Page 7

## CONCLUSION

The foregoing is submitted as a full and complete response to the non-final Office Action mailed August 22, 2005. Applicants assert that the claims are now in condition for allowance and respectfully request that the application be passed to issuance. If the Examiner believes that any informalities remain in the case which may be corrected by Examiner's amendment, or that there are any other issues which can be resolved by a telephone interview, a telephone call to the undersigned agent at (404) 815-6102 is respectfully solicited.

No additional fees are believed due, however, the Commissioner is hereby authorized to charge any deficiencies that may be required or credit any overpayment to Deposit Account Number 11-0855.

Respectfully submitted,

KILPATRICK STOCKTON LLP



By: Elena S. Polovnikova, Ph.D.  
Patent Agent  
Reg. No.: 52,130

KILPATRICK STOCKTON LLP  
1100 Peachtree Street, Suite 2800  
Atlanta, GA 30309-4530  
Phone: (404) 815-6500  
Facsimile: (404) 815-6555  
Atty. Docket: 54785-2141 (54785-299503)